Logo

SXTC

China SXT Pharmaceuticals, Inc.

SXTC

China SXT Pharmaceuticals, Inc. • NASDAQ
$1.44 ▲ 1.41% (+0.02)
Market Cap $167.08 M
52w High $5.70
52w Low $0.30
Dividend Yield 0%
P/E -0.62
Volume 270.10K
Outstanding Shares 116.03M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2025 $455.709K $1.137M $-1.251M -274.417% $-0.51 $-1.014M
Q3-2025 $455.709K ▲ $1.137M ▲ $-1.251M ▼ -274.417% ▼ $-0.51 ▲ $-1.014M ▼
Q2-2025 $414.745K $386.511K $-401.284K -96.754% $-0.99 $-284.864K
Q1-2025 $414.745K ▼ $386.511K ▲ $-401.284K ▼ -96.754% ▼ $-0.99 ▼ $-284.864K ▼
Q4-2024 $494.457K $-3.284M $3.299M 667.159% $2.67 $3.679M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $18.099M ▼ $21.664M $6.224M $15.44M
Q3-2025 $18.237M ▼ $21.664M ▼ $6.224M ▼ $15.44M ▲
Q2-2025 $18.513M $30.997M $15.962M $15.035M
Q1-2025 $18.513M ▲ $30.997M ▲ $15.962M ▲ $15.035M ▲
Q4-2024 $12.07M $23.127M $9.197M $13.93M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2025 $-1.251M $-494.077K $11.486K $580.989K $0 $-495.089K
Q3-2025 $-1.251M ▼ $-494.077K ▲ $11.486K ▼ $580.989K ▼ $0 $-495.089K ▲
Q2-2025 $-401.284K $-678.59K $20.272K $3.619M $0 $-678.59K
Q1-2025 $-401.284K ▼ $-678.59K ▼ $20.272K ▲ $3.619M ▲ $0 ▼ $-678.59K ▼
Q4-2024 $3.299M $-674.243K $3.392K $918.654K $306.083K $-677.775K

Five-Year Company Overview

Income Statement

Income Statement The income statement picture is weak. Public data suggest little to no meaningful revenue in recent years, while the company continues to report losses. That means the business does not appear to be generating enough sales to cover even its basic operating costs. Earnings per share have been deeply negative, which, combined with repeated share consolidations, points to heavy value erosion for existing shareholders over time. Overall, the core business seems either very small, largely inactive, or unable to scale to profitable levels so far.

Balance Sheet

Balance Sheet The balance sheet is very light. Total assets and shareholder equity are small, which indicates a modest operational footprint and limited financial cushion. On the positive side, the company shows no financial debt, so it is not burdened by interest payments. However, cash levels also appear low, meaning its ability to fund ongoing operations, R&D, or expansion from its own resources is quite constrained. The lack of leverage reduces financial risk, but the thin capital base and limited liquidity raise questions about long-term sustainability without new external funding or a sharp improvement in business performance.

Cash Flow

Cash Flow Reported cash flow figures are essentially flat, which usually means the business is not generating strong positive cash from operations and is not investing heavily either. In practice, this often reflects a very small scale of activity or incomplete recent disclosure. For a drug and TCM manufacturer, the absence of visible investment spending can also suggest that growth and R&D efforts may be limited by financial resources. Without robust operating cash flow, the company may depend on equity raises, grants, or other external sources to keep going and to support any future expansion.

Competitive Edge

Competitive Edge Commercially, China SXT plays in a niche segment of Traditional Chinese Medicine, using the long-established “Suxuantang” brand and a multi-tier product line from basic herbal pieces to more advanced, convenient formulations. This heritage and brand recognition in parts of Eastern China are genuine strengths, especially in a trust-driven TCM market. At the same time, the company is small relative to large Chinese pharma and TCM groups, which likely limits its bargaining power, marketing reach, and ability to absorb regulatory or pricing shocks. Competition in generic and TCM products is intense, and without clear evidence of strong, protected advantages or broad distribution, its position looks more like a specialized niche player than a dominant force. Financial fragility further weakens its competitive stance, as rivals with stronger balance sheets can outspend it in marketing, quality upgrades, and channel expansion.

Innovation and R&D

Innovation and R&D On the innovation side, the company’s strategy is conceptually attractive: making traditional remedies easier to use through “advanced” oral and after-soaking products, leveraging modern quality control, extraction processes, and freeze-drying technologies. It has invested in process technology, earned high-tech enterprise recognition, and built a research center for advanced TCM pieces, all of which suggest a genuine technical focus and some know‑how in modernizing TCM. However, the public information on its actual product pipeline, granted patents, and upcoming launches is thin. Recent disclosures have emphasized share consolidations more than new drugs or landmark studies. That creates uncertainty about how much commercial impact its R&D is really having, especially given its constrained finances, which can limit the scale and speed of future innovation.

Summary

Stepping back, China SXT Pharmaceuticals combines an appealing narrative—modernizing centuries-old TCM under a well-known legacy brand—with a very fragile financial base and limited transparency on growth drivers. Operationally, it appears to have minimal or no meaningful revenue and ongoing losses, with a very small asset base and low cash reserves but no financial debt. Repeated reverse stock splits underline the pressure the company has faced just to remain listed. Its niche focus, brand history, and technical work on advanced TCM pieces offer some differentiation, yet the absence of clear, sizeable commercial activity and a visible innovation pipeline makes the future path highly uncertain. Overall, the story today is less about scaling a proven franchise and more about whether the company can translate its technical and brand foundations into a sustainable, revenue-generating business before financial constraints become too tight.